BioSpace News Archive

Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational parainfluenza virus 5 -based vector, announced the enrollment of the first participant in a Phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV in Charleston, South Carolina.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that its needle-free injection system and accessories, also known as InsuJet™, has been approved by Health Canada specifically for the needle-free delivery of insulin.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.

The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic ® network, announced it will report its second quarter 2022 financial results on Thursday, August 4, 2022, after the market close.

DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine outcomes trial with publication of ‘ Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022.

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022 , at 4:30 p.m. Eastern Time to discuss results for the second quarter ended June 30, 2022.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022, before the U.S. financial markets open.

Karyopharm Therapeutics Inc. and the Menarini Group today announced that the European Commission (EC) has granted Marketing Authorisation for NEXPOVIO.